AENEAS2: Aumolertinib Plus Chemotherapy Extends PFS in EGFR-Mutant Advanced NSCLC

First-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC) continues to evolve from EGFR tyrosine kinase inhibitor (TKI) monotherapy toward more intensive strategies designed to delay acquired resistance and prolong disease control. The phase III AENEAS2 trial provides new evidence supporting this approach.

In treatment-naive patients with locally advanced or metastatic NSCLC harboring sensitizing EGFR mutations, adding platinum-pemetrexed chemotherapy to the third-generation EGFR TKI aumolertinib significantly prolonged progression-free survival (PFS) compared with aumolertinib alone.

Median PFS reached 28.9 months with combination therapy versus 18.9 months with aumolertinib monotherapy, corresponding to a 53% reduction in the risk of disease progression or death. The improvement came at the cost of substantially greater hematologic toxicity, making the balance between efficacy and treatment burden central to interpreting the results.

The findings were published in The Lancet Oncology on June 16, 2026. Why Test Chemotherapy Upfront With an EGFR TKI? Third-generation EGFR TKIs have become highly effective first-line treatments for advanced NSCLC with sensitizing EGFR mutations.

Nevertheless, acquired resistance remains inevitable for most patients, ultimately resulting in disease progression. AENEAS2 was designed to determine whether attacking the disease more intensively from treatment initiation could delay that progression. The strategy combined continuous EGFR inhibition with platinum-based chemotherapy and pemetrexed, followed by maintenance aumolertinib plus pemetrexed.

The central question was therefore not whether aumolertinib is active in EGFR-mutant NSCLC, but whether adding chemotherapy upfront can extend disease control beyond that achieved with the TKI alone. A Large Randomized Phase III Trial AENEAS2 was an open-label, multicentre, randomized phase III study conducted across 60 hospitals in China.

Eligible patients were adults with previously untreated locally advanced or metastatic NSCLC harboring sensitizing EGFR mutations: EGFR exon 19 deletion EGFR L858R either alteration with additional EGFR mutations Patients were required to have an ECOG performance status of 0–1. Neurologically stable brain metastases were permitted, an important feature given the frequency of central nervous system involvement in EGFR-mutated NSCLC.

Previous EGFR TKI treatment was not allowed. Between August 2021 and June 2024, 624 patients were randomly assigned 1:1: 310 patients received aumolertinib plus chemotherapy, while 314 patients received aumolertinib monotherapy. Median age was 59 years, and 54% of participants were women.

Randomization was stratified by EGFR mutation subtype and the presence or absence of brain metastases at baseline. What Treatment Did Patients Receive? Patients in the monotherapy group received: Aumolertinib 110 mg orally once daily.

Patients assigned to combination treatment received Aumolertinib 110 mg once daily + pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 or carboplatin AUC5 every 3 weeks for 4–6 cycles. After completion of platinum chemotherapy, patients continued maintenance treatment with Aumolertinib 110 mg daily + pemetrexed 500 mg/m2 every 3 weeks.

The primary endpoint was PFS assessed by blinded independent central review according to RECIST 1.1. PFS Improved by 10 Months At the June 18, 2024 data cutoff, median follow-up was 23.4 months. The study met its primary endpoint.

Median blinded-independent-review PFS was: 28.9 months with aumolertinib + chemotherapy versus 18.9 months with aumolertinib alone The hazard ratio was: HR 0.47; 95% CI, 0.37–0.60; p<0.0001 This represents a 53% relative reduction in the risk of progression or death with upfront combination therapy.

The approximately 10-month difference in median PFS is clinically notable and demonstrates that chemotherapy can meaningfully extend disease control when incorporated from the beginning of aumolertinib treatment. What Does the PFS Result Mean Clinically? A hazard ratio of 0.47 represents a substantial treatment effect.

Importantly, this is not simply a comparison between different EGFR TKIs. Both treatment groups received the same targeted therapy, meaning that the PFS separation reflects the additional contribution of chemotherapy within this trial. The results therefore support the biological and clinical rationale for early treatment intensification rather than reserving chemotherapy exclusively for later progression.

However, longer PFS alone does not establish that combination therapy should be preferred for every patient. The treatment comes with a considerably greater toxicity burden, and overall survival data remain immature. The eventual clinical value of the regimen will therefore depend on whether longer disease control translates into durable survival benefit while maintaining an acceptable quality of life.

Toxicity Increased Substantially With Combination Therapy The efficacy advantage was accompanied by markedly higher rates of hematologic toxicity. The most common grade 3–4 adverse events were: Decreased neutrophil count 55% with combination therapy vs 1% with monotherapy Decreased white blood cell count: 34% vs <1% Decreased platelet count: 20% vs 1% These differences reflect the expected additional toxicity associated with platinum-pemetrexed chemotherapy.

Serious adverse events also occurred more frequently with combination treatment: 36% with aumolertinib + chemotherapy versus 17% with aumolertinib alone Among the most frequent serious events in the combination group were thrombocytopenia, neutropenia, leukopenia and anemia. According to the investigators, toxicities were generally managed through supportive care and dose modification consistent with routine clinical practice.

Treatment-Related Deaths Were Uncommon Treatment-related deaths occurred in: 1 patient (<1%) in the combination group, owing to encephalopathy and 2 patients (1%) receiving monotherapy, owing to pulmonary embolism and respiratory failure with circulatory collapse Although uncommon, these events reinforce the importance of interpreting efficacy together with safety rather than considering PFS in isolation.

Efficacy Versus Treatment Burden AENEAS2 raises an increasingly important question in EGFR-mutated NSCLC: Should every eligible patient receive the most intensive first-line treatment, or should therapy be individualized according to disease burden and patient characteristics? A median PFS approaching 29 months represents prolonged disease control.

At the same time, adding chemotherapy transforms a relatively convenient oral targeted therapy into a regimen requiring intravenous platinum treatment, ongoing pemetrexed maintenance, laboratory surveillance and management of potentially substantial myelosuppression. The decision is therefore likely to involve more than the magnitude of the PFS benefit.

In clinical practice, factors such as performance status, comorbidity, disease burden, tolerance for chemotherapy, patient preference, baseline marrow reserve and the need for rapid disease control may influence whether treatment intensification is appropriate. AENEAS2 demonstrates that the combination is more effective at delaying progression.

It does not establish that combination treatment necessarily offers the optimal risk-benefit balance for every individual patient. Brain Metastases Are an Important Part of the Trial Design Patients with neurologically stable brain metastases were eligible, and randomization was stratified according to baseline CNS involvement.

This strengthens the clinical relevance of the study because brain metastases are a major concern throughout the course of EGFR-mutated NSCLC. However, the summary provided does not report detailed intracranial PFS, CNS response rates or CNS progression outcomes. Those data will be particularly valuable in understanding whether the chemotherapy component adds meaningful CNS protection beyond that provided by a third-generation EGFR TKI.

Overall Survival Remains the Major Unanswered Question The current AENEAS2 report establishes a clear PFS advantage, but overall survival follow-up is still required. This distinction matters. A strategy that uses chemotherapy earlier may delay first progression but can also alter subsequent treatment sequencing.

Determining whether earlier chemotherapy ultimately extends survival requires mature OS data. Longer follow-up will therefore be essential to determine whether the large PFS advantage becomes an OS advantage and to better characterize the long-term toxicity and treatment burden of prolonged combination therapy.

Until then, AENEAS2 should be interpreted as strong evidence for improved disease control rather than definitive evidence of improved survival. AENEAS2 and the Shift Toward Upfront Intensification The results reinforce a broader treatment principle emerging in oncogene-driven NSCLC: highly effective targeted therapy does not necessarily need to be used as monotherapy.

Combining molecularly targeted treatment with conventional systemic therapy from the beginning may suppress a broader range of tumor clones and delay the development of clinically apparent resistance. AENEAS2 provides phase III evidence that this principle can produce a substantial PFS improvement with aumolertinib.

The trade-off is equally clear: greater disease control requires greater treatment intensity. For clinicians and patients, the central challenge will be identifying who derives enough additional benefit to justify that added toxicity. OncoDaily Takeaway AENEAS2 establishes aumolertinib plus platinum-pemetrexed chemotherapy as a highly active first-line strategy for advanced EGFR-mutated NSCLC.

The combination extended median PFS from 18.9 to 28.9 months, with an HR of 0.47, representing a 53% reduction in the risk of progression or death. That magnitude of benefit is clinically meaningful. However, it was accompanied by substantially greater myelosuppression and a doubling of serious adverse events from 17% to 36%.

The study therefore strengthens the case for upfront treatment intensification while simultaneously emphasizing the need for individualized decision-making. The key outstanding question is now whether the substantial PFS improvement will translate into longer overall survival and sufficient long-term clinical benefit to offset the additional toxicity and treatment burden.

Until mature OS data are available, AENEAS2 provides compelling evidence for better disease control, but not yet the final answer regarding the optimal first-line strategy for every patient with EGFR-mutated advanced NSCLC. Source Li Z, Hu J, Chen J, et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.

The Lancet Oncology. Published June 16, 2026. DOI: 10.1016/S1470-2045(26)00090-2.